A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes

PURPOSE: The incidence of bone metastasis in advanced breast cancer exceeds 70%. Bortezomib (Bzb), a proteasome inhibitor used for the treatment of multiple myeloma, also promotes bone formation. We tested the hypothesis that proteasome inhibitors can ameliorate breast cancer osteolytic disease. EXP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jones, Marci D., Liu, Julie C., Barthel, Thomas K., Hussain, Sadiq, Lovria, Erik, Cheng, Dengfeng, Schoonmaker, Jesse.A., Mulay, Sudhanshu, Ayers, David C., Bouxsein, Mary L., Stein, Gary S., Mukherjee, Siddhartha, Lian, Jane B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2955762/
https://ncbi.nlm.nih.gov/pubmed/20843837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-3293
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados